度拉糖肽对糖尿病肾病尿蛋白的影响
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v4i4.5434
Abstract
糖尿病肾病作为常见的糖尿病微血管并发症以及成为终末期肾病的第一大病因,尚缺乏有效治疗手段来延缓其进展。近年来新型降糖药物GLP-1以其抗炎、促进尿钠排泄、改善内皮细胞功能等潜在肾脏获益机制为糖尿病肾病的治疗带来了新的进展,度拉糖肽作为国内新上市的GLP-1RA周制剂,大大提高了患者的依从性,为探究GLP-1RA对糖尿病肾病疗效的研究提供了新的方向。
Keywords
糖尿病；2型糖尿病；糖尿病肾病；度拉糖肽；胰高血糖素样肽-1
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Cheng H T, Xu X, Lim P S, et al. Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015.[J]. Diabetes care,2021,44(1):89-97.
[2] 中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(04):292-344.
[3] Persson, F., R. Borg and P. Rossing, A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. Annals of Translational Medicine,2021.9(8):716.
[4] CE, A. and H. KL, Pathology identifies glomerular trea tment targets in diabetic nephropathy. Kidney research and clinical practice,2018.37(2):106-111.
[5] NM, M., H. AA and M. EE, Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract. Frontiers in cell and deve lopmental biology, 2021.9:703966.
[6] DJ, D., GLP-1 physiology informs the pharmacotherapy of obesity. Molecular metabolism, 2021:101351.
[7] 崔佳乐,GLP-1RA在2型糖尿病中的应用进展. 医学综述,2021.27(4):778-782,787.
[8] Keyhani-Nejad, F., et al., Endogenously released GIP reduces and GLP-1 increases hepatic insulin extraction.Peptides, 2020. 125:170231.
[9] Salehi, M., B.A. Aulinger and D.A. D'Alessio, Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev,2008.29(3):367-79.
[10] Wang, X., et al., Glucagon-like peptide-1 causes pan creatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechan ism.Endocrinology,2001.142(5):1820-7.
[11] Sbraccia, et al., GLP-1 receptor independent pathw ays: emerging beneficial effects of GLP-1 breakdown produc ts.Eating and weight disorders: EWD,2017.
[12] 王仙花,GLP-1类似物——度拉鲁肽研究进展.中国医药科学,2020,10(03):34-37.
[13] H, H., et al., GLP-1 analog liraglutide protects agai nst oxidative stress and albuminuria in streptozotocin-indu ced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism: clinical and experimental, 2012.61(10):1422-34.
[14] Carraro-Lacroix, L.R., G. Malnic and A.C.C. Girardi,Regulation of Na+ /H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. American Journal of Physiology-Renal Physiology,2009. 297(6): p. F1647-F1655.
[15] AVR, H. and S. CM, Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. American jou rnal of physiology. Renal physiology, 2020. 318(2): p. F443-F454.
[16] Crajoinas, R.O., et al., Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. American Journal of PhysiologyRenal Physiology,2011.301(2):p.F355-F363
[17] Winiarska, A., et al., Inflammation and Oxidative Stre ss in Diabetic Kidney Disease: The Targets for SGLT2 Inhibi tors and GLP-1 Receptor Agonists. International Journal of Molecular Sciences,2021.22(19):p.10822.
[18] W, Y., et al., Protein kinase C and protein kinase A are involved in the protection of recombinant human glucagonlike peptide-1 on glomeruli and tubules in diabetic rats. Journal of diabetes investigation, 2019. 10(3): p. 613-625.
[19] Chang, J., et al., Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells. BMC Pharmacology andToxicology,2017.18(1).
[20] Wang, X., et al., An experimental study of exenatide effects on renal injury in diabetic rats. Acta Cirurgica Brasi leira, 2019. 34(1).
[21] Patel V J, Joharapurkar A A, Kshirsagar S G, et al. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus[J]. World journal of diabetes, 2018, 9(6):80-91.
[22] 朱超霞,利拉鲁肽对初发2型糖尿病伴肥胖患者代谢紊乱的调节作用[J].深圳中西医结合杂志,2019,29(16):156-157.
[23] Rojano Toimil, A. and A. Ciudin, GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes. Journal of Clinical Medicine, 2021. 10(17): p. 3955.
[24] Ye, Y., et al., Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflam matory factor TNF-α-mediated NF-κB and MAPK pathway. Obesity Research & Clinical Practice, 2019.13(4): p. 385-390.
[25] Li, Q., et al., GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells. Scientific Reports, 2017. 7(1).
[26] YK, L., et al., The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis. Pharmacological research, 2018. 131: p. 102-111.
[27] Jia, Y., et al., Exendin-4 ameliorates high glucoseinduced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells. Experimental & Molecu lar Medicine,2018.50(5):p.1-13.
[28] Tuttle, K.R., et al., Dulaglutide versus insulin glargi ne in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The lancet. Diabetes & endocrinology, 2018.6(8): p. 605-617.
[29] Tuttle, K.R., et al., Effects of once-weekly dulaglut ide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes, Obesity andMetabolism,2017.19(3):p.436-441.
[30] Lakshmanan, M., et al., Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet (British edition), 2019.394(10193): p.131-138.
[2] 中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(04):292-344.
[3] Persson, F., R. Borg and P. Rossing, A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. Annals of Translational Medicine,2021.9(8):716.
[4] CE, A. and H. KL, Pathology identifies glomerular trea tment targets in diabetic nephropathy. Kidney research and clinical practice,2018.37(2):106-111.
[5] NM, M., H. AA and M. EE, Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract. Frontiers in cell and deve lopmental biology, 2021.9:703966.
[6] DJ, D., GLP-1 physiology informs the pharmacotherapy of obesity. Molecular metabolism, 2021:101351.
[7] 崔佳乐,GLP-1RA在2型糖尿病中的应用进展. 医学综述,2021.27(4):778-782,787.
[8] Keyhani-Nejad, F., et al., Endogenously released GIP reduces and GLP-1 increases hepatic insulin extraction.Peptides, 2020. 125:170231.
[9] Salehi, M., B.A. Aulinger and D.A. D'Alessio, Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev,2008.29(3):367-79.
[10] Wang, X., et al., Glucagon-like peptide-1 causes pan creatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechan ism.Endocrinology,2001.142(5):1820-7.
[11] Sbraccia, et al., GLP-1 receptor independent pathw ays: emerging beneficial effects of GLP-1 breakdown produc ts.Eating and weight disorders: EWD,2017.
[12] 王仙花,GLP-1类似物——度拉鲁肽研究进展.中国医药科学,2020,10(03):34-37.
[13] H, H., et al., GLP-1 analog liraglutide protects agai nst oxidative stress and albuminuria in streptozotocin-indu ced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism: clinical and experimental, 2012.61(10):1422-34.
[14] Carraro-Lacroix, L.R., G. Malnic and A.C.C. Girardi,Regulation of Na+ /H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. American Journal of Physiology-Renal Physiology,2009. 297(6): p. F1647-F1655.
[15] AVR, H. and S. CM, Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. American jou rnal of physiology. Renal physiology, 2020. 318(2): p. F443-F454.
[16] Crajoinas, R.O., et al., Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. American Journal of PhysiologyRenal Physiology,2011.301(2):p.F355-F363
[17] Winiarska, A., et al., Inflammation and Oxidative Stre ss in Diabetic Kidney Disease: The Targets for SGLT2 Inhibi tors and GLP-1 Receptor Agonists. International Journal of Molecular Sciences,2021.22(19):p.10822.
[18] W, Y., et al., Protein kinase C and protein kinase A are involved in the protection of recombinant human glucagonlike peptide-1 on glomeruli and tubules in diabetic rats. Journal of diabetes investigation, 2019. 10(3): p. 613-625.
[19] Chang, J., et al., Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells. BMC Pharmacology andToxicology,2017.18(1).
[20] Wang, X., et al., An experimental study of exenatide effects on renal injury in diabetic rats. Acta Cirurgica Brasi leira, 2019. 34(1).
[21] Patel V J, Joharapurkar A A, Kshirsagar S G, et al. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus[J]. World journal of diabetes, 2018, 9(6):80-91.
[22] 朱超霞,利拉鲁肽对初发2型糖尿病伴肥胖患者代谢紊乱的调节作用[J].深圳中西医结合杂志,2019,29(16):156-157.
[23] Rojano Toimil, A. and A. Ciudin, GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes. Journal of Clinical Medicine, 2021. 10(17): p. 3955.
[24] Ye, Y., et al., Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflam matory factor TNF-α-mediated NF-κB and MAPK pathway. Obesity Research & Clinical Practice, 2019.13(4): p. 385-390.
[25] Li, Q., et al., GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells. Scientific Reports, 2017. 7(1).
[26] YK, L., et al., The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis. Pharmacological research, 2018. 131: p. 102-111.
[27] Jia, Y., et al., Exendin-4 ameliorates high glucoseinduced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells. Experimental & Molecu lar Medicine,2018.50(5):p.1-13.
[28] Tuttle, K.R., et al., Dulaglutide versus insulin glargi ne in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The lancet. Diabetes & endocrinology, 2018.6(8): p. 605-617.
[29] Tuttle, K.R., et al., Effects of once-weekly dulaglut ide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes, Obesity andMetabolism,2017.19(3):p.436-441.
[30] Lakshmanan, M., et al., Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet (British edition), 2019.394(10193): p.131-138.
Copyright © 2022 赵雨, 陈云霞, 王唯一, 齐珊珊
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License